Understanding how SOCS1 affects uveal melanoma treatment with immunotherapy
Official title: SOCS1 is a crucial regulator for uveal melanoma response to immunotherapy
Funded at University of Texas El Paso · NIH-10897221 · Data updated 2026-11-12
This study is looking at how a protein called SOCS1 affects how well uveal melanoma patients respond to immunotherapy, with the hope of finding better ways to treat this tough cancer by understanding why current treatments aren't working as well as they should.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas El Paso NIH-funded |
| Lab location | 1 site (El Paso, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $153,500 |
| NIH project number | 5R16GM145559-03 |
| Project ID | NIH-10897221 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with uveal melanoma, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with other types of melanoma or those who have not been diagnosed with uveal melanoma may not benefit from this research.
What this research studies
This research investigates the role of SOCS1, a protein that regulates immune responses, in how uveal melanoma (UM) patients respond to immunotherapy. The study aims to identify the mechanisms behind the poor effectiveness of current treatments for UM, which has not benefited from existing therapies like immune checkpoint inhibitors. By analyzing tumor samples from patients, the researchers hope to uncover important biomarkers that could predict treatment responses and improve therapeutic strategies for UM. The ultimate goal is to enhance the effectiveness of immunotherapy for patients suffering from this challenging form of cancer.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy options for uveal melanoma patients, potentially increasing survival rates and treatment effectiveness.
How similar studies have gone: While there has been significant research on immunotherapy in other melanoma types, the specific role of SOCS1 in uveal melanoma is less explored, making this a novel investigation.
Where this research is happening
-
University of Texas El Paso
El Paso, United States Active
Researchers
- Principal investigator: Qin, Yong — University of Texas El Paso
- Study coordinator: Qin, Yong
Related research
Other NIH-funded projects on the same topics.
-
SOCS1's role in uveal melanoma response to immunotherapy
This project looks at whether levels of a protein called SOCS1 can predict and help improve immunotherapy response for people with uveal melanoma.
-
Combining a vaccine and T cell therapy to treat uveal melanoma
This study is testing a new way to treat metastatic uveal melanoma by using a special vaccine and a personalized T cell therapy to help your immune system fight the cancer better.
-
Targeting serotonin receptors to boost a cancer cell weakness in uveal melanoma
A small funding project tests whether blocking the serotonin HTR2B receptor can weaken mutant GNAQ/GNA11-driven uveal melanoma cells to help fight metastatic eye cancer.
-
Overcoming Melanoma Treatment Resistance with a Special IL-18 Approach
A Yale-led project tests a special engineered IL-18 immune signal to help melanoma patients who don’t fully respond to current therapies.
-
Prebiotic diet to boost gut health and improve immunotherapy response in melanoma
A diet-based approach using prebiotic foods and nutrition counseling is studied alongside standard immunotherapy to help melanoma patients respond better and reduce side effects.
-
Dual mRNA therapeutics aimed at liver metastasis from uveal melanoma
A new approach uses two mRNA-based therapies designed to target liver metastases in adults with uveal melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.